Search the Newsreel

Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aldeyra Therapeutics, Inc. (ALDX) who bought securities prior to November 3, 2023. The investigation focuses on whether Aldeyra's officers and/or directors engaged in corporate wrongdoing. The firm encourages affected shareholders …

Aldeyra Therapeutics Inc. (ALDX) Stock Price | Live Quotes & Charts | NASDAQ

Aldeyra Therapeutics Inc (ALDX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Aldeyra Therapeutics Inc (ALDX) has an earnings forecast score of 8.67, ranking 75th in the Biotechnology & Medical Research industry. Analysts have set an average price target of $9.50, with a strong "Buy" rating based on the consensus of 6 analysts. The company's expected …

Aldeyra Therapeutics (NASDAQ:ALDX) Announces Quarterly Earnings Results

Aldeyra Therapeutics (NASDAQ:ALDX) reported a quarterly loss of $0.09 per share, missing analyst estimates by $0.01. Shares dropped 0.6% to $1.59, trading below their moving averages, and the company has a market capitalization of $95.9 million. Despite the earnings miss, CEO Todd C. Brady …

Aldeyra Therapeutics Inc (ALDX) Stock News Today

Aldeyra Therapeutics, Inc. Q2 2026: Net loss $5.45M, EPS $(0.09) — 10-Q Summary

Aldeyra Therapeutics, Inc. reported a significant reduction in its net loss for Q2 2026, reaching $5.45M compared to $9.77M in Q2 2025, with diluted EPS improving to $(0.09). This improvement is attributed to reduced R&D activity and controlled spending, as the company continues to …

ALDX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) and its officers. The lawsuit alleges that the company made false and misleading statements regarding the inconsistent results of its reproxalap clinical trials. Investors who purchased Aldeyra securities …

Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aldeyra Therapeutics, Inc. (ALDX) on behalf of investors who purchased securities before November 3, 2023, and still hold them. The investigation focuses on whether Aldeyra's officers or directors engaged in corporate wrongdoing. The firm …

Aldeyra Therapeutics Leases New Concord Headquarters Space

Aldeyra Therapeutics (NASDAQ: ALDX) has signed a lease for a new corporate headquarters located at 23 Bradford Street, Concord, Massachusetts, encompassing approximately 4,067 square feet. The lease, which commences on September 1, 2026, and runs through September 30, 2029, involves an initial monthly base …

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Short Interest Update

Aldeyra Therapeutics (NASDAQ:ALDX) experienced a 36.7% decrease in short interest by July 15th, totaling 3.59 million shares, representing 6.8% of outstanding shares and a two-day days-to-cover ratio. CEO Todd C. Brady recently increased his stake by nearly 17% through a purchase of 250,000 shares …

Aldeyra Therapeutics (NASDAQ: ALDX) leases new Concord headquarters space

Aldeyra Therapeutics (NASDAQ: ALDX) has signed a lease for a new corporate headquarters located at 23 Bradford Street, Concord, Massachusetts, encompassing approximately 4,067 square feet. The lease, which commences on September 1, 2026, and runs through September 30, 2029, involves an initial monthly base …

Aldeyra Therapeutics Inc (ALDX) Valuation: PE, PB & Fair Value Analysis

Aldeyra Therapeutics Inc (ALDX) currently holds a valuation score of 8.18, placing it 160th out of 384 companies in the Biotechnology & Medical Research industry. The company's P/E ratio is -3.54, which is significantly below its recent high and above its recent low. Important …

Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Aldeyra Therapeutics, Inc. (ALDX). The firm is encouraging investors who purchased Aldeyra securities before November 3, 2023, and still hold them, to come forward and assist in the investigation. They …

Aldeyra Therapeutics Inc (ALDX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Aldeyra Therapeutics Inc (ALDX), detailing its current price momentum score, support and resistance levels, and insights from various technical indicators and moving averages. The stock (ALDX) is currently trading within a range, with indicators showing a mix …

BlackRock (ALDX holder) discloses 1.7% Aldeyra Therapeutics stake in amended 13G

BlackRock, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 1,045,764 common shares in Aldeyra Therapeutics, Inc. (ALDX), which constitutes a 1.7% stake in the company. BlackRock maintains sole voting and dispositive power over all these shares. This filing specifies that …

Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aldeyra Therapeutics, Inc. (ALDX) on behalf of investors who purchased securities prior to November 3, 2023. The investigation aims to determine if the company and its officers engaged in corporate wrongdoing. The firm encourages …

Aldeyra Therapeutics Inc (ALDX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Aldeyra Therapeutics Inc (ALDX). However, it states that relevant data for business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page displays basic stock information and a placeholder …

Aldeyra Therapeutics Inc (ALDX) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Aldeyra Therapeutics Inc (ALDX), detailing its volatility, financial risks, and investment risks. It presents various financial metrics such as Beta, VaR, Maximum Drawdown, Volatility, Sharpe Ratio, Skewness, Downside Risk-Adjusted Return, and Liquidity. The data covers different timeframes, …

Aldeyra Therapeutics, Inc. Revenue Breakdown – NASDAQ:ALDX

This article from TradingKey provides a revenue breakdown for Aldeyra Therapeutics Inc (ALDX). However, it states that relevant data for business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page displays basic stock information and a placeholder …

Aldeyra Therapeutics Inc (ALDX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Aldeyra Therapeutics Inc (ALDX), outlining its major shareholders, institutional holdings, and shareholder activity. It identifies top shareholders like Knoll Capital Management and Perceptive Advisors, categorizes shareholder types, and presents quarterly institutional shareholding data and recent changes in …

ALDX|Aldeyra Therapeutics Inc|Price:1.520|Chg%:-0.030

This article provides a comprehensive stock analysis of Aldeyra Therapeutics Inc (ALDX) using TradingKey's proprietary scoring system. It highlights the company's strong fundamentals and high growth potential, fair valuation within its industry, and high institutional ownership. Despite recent stock market weakness, analysts have rated …

ALDX Q2'26 Earnings: revenue estimate is 0 USD

Aldeyra Therapeutics, Inc. (ALDX) is scheduled to announce its Q2'26 earnings on July 31st. The company is projected to report 0 USD in revenue and an EPS of (0.08) USD for the quarter. This article provides a brief overview of past and estimated revenue …

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Investors to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Aldeyra Therapeutics, Inc. (ALDX) regarding potential corporate wrongdoing by the company and its officers/directors. Investors who purchased Aldeyra securities before November 3, 2023, and still hold them, are urged to contact the firm to …

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Reach Out

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Aldeyra Therapeutics, Inc. (ALDX) and its officers/directors. The firm is encouraging investors who purchased Aldeyra securities before November 3, 2023, and still hold them, to contact them to assist with …

Price to sales forward of Aldeyra Therapeutics, Inc. – FWB:137

This article displays the "Price to sales forward" metric for Aldeyra Therapeutics, Inc. (FWB:137) as presented on TradingView. The content is a data point from a financial platform, showing a specific financial ratio for the company, and highlights that the market was closed with …

Spotlight On Aldeyra Therapeutics And 2 Other Prominent Penny Stocks

ALDX Forecast — Price Target — Prediction for 2027

Aldeyra Therapeutics, Inc. Actuals & Estimates (NASDAQ:ALDX)

ALDX Q1 2026 Earnings: Narrowed Loss Beats Estimates as Pipeline Progress Continues - Earnings Trend Analysis

ALDX Q1 2026 Earnings: Narrower Loss Beats Estimates as Pipeline Progress Continues - Estimate Uncertainty

Aldeyra Therapeutics Q1 2026 Earnings: Narrower Loss Surpasses Expectations, Stock Rises - Earnings Season Review

Aldeyra Therapeutics And 2 More Promising Penny Stocks For Your Watchlist

Aldeyra Eyes Growth as CEO Prepares for Key Conference